Purpose This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor with a histone deacetylase abexinostat in conjunction with pazopanib to improve response and reverse resistance. in renal cell carcinoma (RCC). Outcomes Fifty-one sufferers with RCC (N = 22) had been enrolled, including 30 (59%) with a number of… Continue reading Purpose This phase I trial evaluated epigenetic modulation of vascular endothelial